Axon Enterprise, Inc. (NASDAQ:AXON) Insider Sells $875,621.80 in Stock

Axon Enterprise, Inc. (NASDAQ:AXON) insider Jeffrey C. Kunins sold 1,370 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $639.14, for a total value of $875,621.80. Following the sale, the insider now directly owns 125,950 shares in the company, valued at $80,499,683. This trade represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Axon Enterprise Stock Up 0.9 %

NASDAQ:AXON opened at $615.68 on Friday. The company has a market cap of $46.95 billion, a price-to-earnings ratio of 159.09, a price-to-earnings-growth ratio of 14.19 and a beta of 1.01. Axon Enterprise, Inc. has a twelve month low of $241.72 and a twelve month high of $698.67. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The stock has a fifty day simple moving average of $555.56 and a 200-day simple moving average of $414.18.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Public Sector Pension Investment Board grew its stake in Axon Enterprise by 19.2% in the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after acquiring an additional 500 shares in the last quarter. CIBC Asset Management Inc grew its stake in Axon Enterprise by 9.2% in the third quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after purchasing an additional 895 shares in the last quarter. Foundations Investment Advisors LLC purchased a new position in Axon Enterprise during the 3rd quarter worth $221,000. Sequoia Financial Advisors LLC raised its position in Axon Enterprise by 4.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 81 shares in the last quarter. Finally, Axxcess Wealth Management LLC purchased a new stake in shares of Axon Enterprise in the 3rd quarter worth $814,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AXON shares. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. JMP Securities upped their target price on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Robert W. Baird lifted their price target on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. Needham & Company LLC upped their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Northland Securities lifted their target price on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $488.67.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.